- 1 Improved limit of detection for zoonotic Plasmodium knowlesi and P. cynomolgi
- 2 surveillance using reverse transcription for total nucleic acid preserved samples
- 3 or dried blood spots

12

13

- 5 Kamil A Braima^{1*}, Kim A Piera^{1*}, Inke ND Lubis^{1,2}, Rintis Noviyanti³, Giri S Rajahram^{5,6,7},
- 6 Pinkan Kariodimedjo⁴, Irbah RA Nainggolan², Ranti Permatasari², Leily Trianty³, Ristya
- 7 Amalia⁴, Sitti Saimah binti Sakam⁵, Angelica F Tan^{1,5}, Timothy William^{5,6}, Jacob AF
- 8 Westaway^{1,8}, PingChin Lee^{9,10}, Sylvia Daim¹¹, Henry Surendra^{12,13}, Nathaniel Christy¹⁴,
- 9 Andrew G Letizia¹⁴, Christopher L Peatey¹⁵, Mohd Arshil Moideen¹⁶, Bridget E Barber^{1,5,17},
- 10 Colin J Sutherland¹⁸, Nicholas M Anstey^{1,5}, Matthew J Grigg^{1,5}
- 11 *Equal contribution

Affiliations

- 14 1. Global and Tropical Health Division, Menzies School of Health Research and Charles Darwin University,
- Darwin, Northern Territory, Australia
- 16 2. Faculty of Medicine, Universitas Sumatera Utara, Medan, Sumatera Utara, Indonesia
- 17 3. Eijkman Research Center for Molecular Biology, BRIN, Indonesia
- 4. Exeins Health Initiative, Jakarta, Indonesia
- 19 5. Infectious Diseases Society Kota Kinabalu Sabah-Menzies School of Health Research Clinical Research
- 20 Unit, Kota Kinabalu, Sabah, Malaysia
- 6. Clinical Research Centre-Queen Elizabeth Hospital, Ministry of Health, Kota Kinabalu, Sabah, Malaysia
- 22 7. School of Medicine and Health Sciences, Monash University Malaysia, Kuala Lumpur, Malaysia
- 8. Centre for Tropical Bioinformatics and Molecular Biology, James Cook University, Cairns, Queensland,
- 24 Australia
- 9. Biotechnology Research Institute, Universiti Malaysia Sabah, Kota Kinabalu, Sabah, Malaysia.
- 26 10. Faculty of Science and Natural Resources, Universiti Malaysia Sabah, Kota Kinabalu, Sabah Malaysia.
- 27 Il Faculty of Medicine and Health Sciences, Universiti Malaysia Sabah, Kota Kinabalu, Sabah, Malaysia NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

28 12. Monash University Indonesia, Tangerang, Indonesia 29 13. Oxford University Clinical Research Unit Indonesia, Faculty of Medicine Universitas Indonesia, Jakarta, 30 Indonesia 31 14. U.S. Naval Medical Research Unit INDO PACIFIC, Singapore 32 15. Drug Resistance and Diagnostics, Australian Defence Force Malaria and Infectious Disease Institute, 33 Brisbane, Queensland, Australia 34 16. Malaysian Armed Forces and Faculty of Medicine & Defence Health, National Defence University of 35 Malaysia 36 17. QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia 37 18. Department of Infection Biology, London School of Hygiene & Tropical Medicine, London, United 38 Kingdom 39 **Corresponding authors:** 40 Matthew Grigg, Global Health Division, Menzies School of Health Research, Rocklands 41 Drive, Tiwi, NT 0810, Australia. Email: matthew.grigg@menzies.edu.au 42 43 Inke ND Lubis, Faculty of Medicine, Universitas Sumatera Utara, Jl. Dr. Mansyur No.5, Padang Bulan, Kec. Medan Baru, Kota Medan, Sumatera Utara 20155, Indonesia. Email: 44 45 inkenadia@gmail.com 46 47 **Key words:** zoonotic malaria, *Plasmodium*, *P. knowlesi*, *P. cynomolgi*, *P. vivax*, PCR, reverse 48 transcription, limit of detection, dried blood spots 49 **Short title:** Reverse transcription improves detection of *P. knowlesi* and *P. cynomolgi* 50

51

52

53

ABSTRACT

55 **Background:** Zoonotic P. knowlesi and P. cvnomolgi symptomatic and asymptomatic infections occur across 56 57 endemic areas of Southeast Asia. Most infections are low-parasitemia, with an unknown 58 proportion below routine microscopy detection thresholds. Molecular surveillance tools 59 optimizing the limit of detection (LOD) would allow more accurate estimates of zoonotic 60 malaria prevalence. 61 **Methods:** 62 An established ultra-sensitive *Plasmodium* genus quantitative-PCR (qPCR) assay targeting the 18S rRNA gene underwent LOD evaluation with and without reverse transcription (RT) for P. 63 knowlesi, P. cynomolgi and P. vivax using total nucleic acid preserved (DNA/RNA ShieldTM) 64 65 isolates and archived dried blood spots (DBS). LODs for selected P. knowlesi-specific assays, 66 and reference P. vivax- and P. cynomolgi-specific assays were determined with RT. Assay 67 specificities were assessed using clinical malaria samples and malaria-negative controls. 68 **Results:** 69 The use of reverse transcription improved *Plasmodium* species detection by up to 10,000-fold 70 (Plasmodium genus), 2759-fold (P. knowlesi), 1000-fold (P. vivax) and 10-fold (P. cynomolgi). 71 The median LOD with RT for the Kamau et al. Plasmodium genus RT-qPCR assay was 72 ≤ 0.0002 parasites/ μ L for P. knowlesi and 0.002 parasites/ μ L for both P. cynomolgi and P. 73 vivax. The LODs with RT for P. knowlesi-specific PCRs were: Imwong et al. 18S rRNA 74 (0.0007 parasites/μL); Divis et al. real-time 18S rRNA (0.0002 parasites/μL); Lubis et al. hemi-75 nested SICAvar (1.1 parasites/μL) and Lee et al. nested 18S rRNA (11 parasites/μL). The LOD 76 for P. vivax- and P. cynomolgi-specific assays with RT were 0.02 and 0.20 parasites/μL 77 respectively. For DBS P. knowlesi samples the median LOD for the Plasmodium genus qPCR with RT was 0.08, and without RT was 19.89 parasites/uL (249-fold change); no LOD

improvement was demonstrated in DBS archived beyond 6 years. The Plasmodium genus and

P. knowlesi-assays were 100% specific for Plasmodium species and P. knowlesi detection,

respectively, from 190 clinical infections and 48 healthy controls. Reference *P. vivax*-specific

primers demonstrated known cross-reactivity with *P. cynomolgi*.

Conclusion:

Our findings support the use of an 18S rRNA *Plasmodium* genus qPCR and species-specific

nested PCR protocol with RT for highly-sensitive surveillance of zoonotic and human

Plasmodium species infections.

approaches to emerging zoonotic malaria species.

Author Summary:

The monkey malaria parasite *Plasmodium knowlesi* has been found to increasingly infect humans across Southeast Asia via the bite of it's anopheline mosquito vectors. Human infections with a similar monkey parasite, *Plasmodium cynomologi*, have also been reported. The diagnostic tools commonly used to detect these malaria species are often unable to detect very low-level infections. We aimed to to improve surveillance detection tools and blood sample collection methods to detect these zoonotic malaria species and understand the extent of transmission and the burden of disease. This study validated and compared the use of molecular laboratory assays targeting these species. We found that with the use of reverse transcription, large improvements in the limit of detection were possible, by up to 10,000-fold for initial malaria screening, and up to 2759-fold for specific *P. knowlesi* detection. Findings from this study support the use of ultrasensitive detection tools to improve surveillance

BACKGROUND

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

Plasmodium knowlesi is a unicellular protozoan malaria parasite present across Southeast Asia within the geographical range of its natural monkey hosts and vector mosquitoes (1,2). P. knowlesi is the most common cause of human malaria in Malaysia; capable of causing severe disease comparable to P. falciparum (3–5). Human infections with other genetically similar zoonotic species, such as P. cynomolgi which share the same natural macaque hosts, have also been reported (6). Accurate detection of emerging zoonotic species such as P. knowlesi and P. cynomolgi in co-endemic areas with other human Plasmodium species infections is necessary to understand the geographical extent of zoonotic malaria transmission and to improve regional estimates of the disease burden (7). Improving national malaria control program detection and reporting of low-level P. knowlesi infections is also vital to demonstrate World Health Organization (WHO)-certified elimination for other non-zoonotic malaria species in Southeast Asia (8). Conventional malaria diagnostic methods such as microscopy lack sensitivity and specificity for active surveillance of P. knowlesi due to common low-level sub-microscopic infections and an inability to accurately distinguish other morphologically similar *Plasmodium* species (7,9); notably P. malariae and the early ring stages of P. falciparum (10,11). Similarly, P. cynomolgi microscopically resembles P. vivax in human infections (12,13). Current malaria rapid diagnostic tests which detect circulating Plasmodium species antigens also remain insufficiently sensitive for P. knowlesi passive case detection at the low parasite counts able to produce symptomatic infections (14–16). Multiple molecular methods to detect P. knowlesi have been developed, including both quantitative and conventional qualitative PCR assays (7,17). However, systematic comparisons of the lower limit of detection (LOD) of these assays and exhaustive testing of *Plasmodium* species-specificity are currently lacking (7). The degree to which the LOD is enhanced with a prior reverse transcription (RT) step is not well characterised despite potential benefits in improving the detection of very low-level parasitemia symptomatic or asymptomatic zoonotic *Plasmodium* species infections (18). Specificity for *P. knowlesi* detection also ideally needs to be validated against other macaque zoonotic *Plasmodium* species, including *P. cynomolgi* (7).

To support an improved molecular surveillance workflow for detection of low-level zoonotic *Plasmodium* species infections (7,19), we evaluated an established *Plasmodium* genus and species-specific PCR assays with the inclusion of a reverse transcription step to enhance the LOD in both total nucleic acid preserved media and dried blood spot (DBS) collected samples.

METHODS

Clinical specimen collection and storage

Clinical venous whole blood samples and dried blood spots were collected prior to antimalarial treatment from individuals diagnosed with malaria by routine hospital microscopy, as part of an ongoing prospective malaria study in Sabah, Malaysia between April 2013 and May 2023. Adult healthy individuals were recruited as malaria-negative controls. Additional *P. vivax* clinical cases were enrolled from a prospective malaria study in western Indonesia between Jan 2022 and Aug 2023. Whole blood samples were collected in ethylenediaminetetraacetic acid (EDTA) and a small subset in DNA/RNA ShieldTM (Zymo Research, Irvine, CA, USA) before being frozen at -80°C at the time of enrolment. DBS were concurrently made using 20µL whole blood spotted on Whatman 3M filter paper and then stored in sealed bags with desiccant. A single donated *P. cynomolgi*-infected sample (20) obtained from a macaque host was frozen in glycerolyte and stored in liquid nitrogen prior to thawing, counting and immediately placing in DNA/RNA ShieldTM.

Microscopic parasite count quantification

Microscopic diagnosis of *Plasmodium* species was undertaken by experienced research microscopists using thick and thin Giemsa-stained blood films. Microscopic quantification of parasitemia (parasites per microlitre) was performed using thick blood smears calculated from the number of parasites per 200 white blood cells, multiplied by the individual patient's total white cell count obtained from routine hospital laboratory flow cytometry (21).

Total nucleic acid extraction and PCR amplification

Total nucleic acids were directly extracted from 200 μL of whole blood using a QIAamp® DNA Blood Mini Kit (QIAGEN, Cat. No. 51106), with DNA/RNA Shield™ samples eluted in 50ul AE buffer to account for the preservative dilution factor. DNA and RNA extraction from DBS were carried out using an in-house method, established by Zainabadi *et al*, 2017 (22). Briefly, DBS equivalent to 40μl whole blood was incubated with 900μl lysis buffer at 65°C, with shaking at 250rpm for 90 minutes. Lysate was transferred to QIAamp® DNA Blood Mini Kit (QIAGEN, Cat. No. 51106) columns, washed with modified buffers, dried at 65°C for 10 minutes and eluted in 40μl buffer AE. The primers, annealing temperatures and/or probe sequences for each PCR assay are described in **Table 1**. Real-time PCR amplifications were performed on a QuantStudio™ 6 Flex (Applied Biosystems). Conventional PCR was performed on a DNA thermal cycler (Bio-Rad T100™ thermal cycler). The amplified nested PCR products were separated by electrophoresis using 2% agarose gels, stained by SYBR Safe™ (Invitrogen), and visualised on a UV transilluminator (Gel Doc XR+ imaging system, Bio-Rad). Each PCR amplification included a *Plasmodium* species positive and negative control and molecular weight standards (Applied Biosystems™).

Table 1. Primer sequences and annealing temperatures of *Plasmodium* genus and species-specific PCR assays

Assay ID	PCR assays	Primer / Probe	Sequence (5' – 3')	Annealing temp. (°C)	PCR method	Plasmodium gene target
D1	Kamau et al, 2011 (26)	KamGF	GCTCTTTCTTGATTTCTTGGATG	60	RT-qPCR	18S rRNA
Plasmodium spp. screening	(rRNA template)	KamGR	AGCAGGTTAAGATCTCGTTCG			
spp. screening		KamGP probe	FAM-ATGGCCGTTTTTAGTTCGTG-BHQ1			
Test A (Pk)	Divis et al, 2010 (27)	Plasmo 1	GTTAAGGGAGTGAAGACGATCAGA	60	qPCR	18S rRNA
		Plasmo 2	AACCCAAAGACTTTGATTTCTCATAA			
		Pk probe	FAM-CTCTCCGGAGATTAGAACTCTTAGATTGCT-BHQ1			
Test B (Pk)	Lubis et al, 2017 (29)	SICAfl	GGTCCTCTTGGTAAAGGAGG	55	Hemi-nested	SICAvar
		SICAr1	CCCTTTTTGACATTCGTCC			
		SICAf2	CTTGGTAAAGGAGGACCACG			
		SICAr1	CCCTTTTTGACATTCGTCC			
Test C (Pk)	Lee et al, 2011 (25)	rPLU 1	TCAAAGATTAAGCCATGCAAGTGA			
		rPLU 5	CCTGTTGTTGCCTTAAACTTC			
		Kn1f	CTCAACACGGGAAAACTCACTAGTTTA	66	Nested	18S rRNA
		Kn3r	GTATTATTAGGTACAAGGTAGCAGTATGC			
Test D (Pcyn)	Lee et al, 2011 (25)	CY2F	GATTTGCTAAATTGCGGTCG	66		
		CY4R	CGGTATGATAAGCCAGGGAAGT			
Pk reference	Imwong et al, 2009 (24)	PkF1160	GATGCCTCCGCGTATCGAC	55	Hemi-nested	18S rRNA
		PkF1150	GAGTTCTAATCTCCGGAGAGAAAAGA			
		PkF1140	GATTCATCTATTAAAAATTTGCTTC	50		
		PkR1150	GAGTTCTAATCTCCGGAGAGAAAAGA			
Human- species	Snounou et al. (1993) (23)	rPLU6	TTAAAATTGTTGCAGTTAAAACG	58	Nested	18S rRNA
reference		rPLU5	CCTGTTGTTGCCTTAAACTTC			
		rFAL 1	TTAAACTGGTTTGGGAAAACCAAATATATT			
		rFAL 2	ACACAATGAACTCAATCATGACTACCCGTC			
		rVIV 1	CGCTTCTAGCTTAATCCACATAACTGATAC			
		rVIV 2	ACTTCCAAGCCGAAGCAAAGAAAGTCCTTA			
		rMAL 1	ATAACATAGTTGTACGTTAAGAATAACCGC			
		rMAL 2	AAAATTCCCATGCATAAAAAATTATACAAA			
		rOVA 1	ATCTCTTTTGCTATTTTTTAGTATTGGAGA			
		rOVA 2	GGAAAAGGACACATTAATTGTATCCTAGTG			

Plasmodium species confirmation using reference PCR

A validated reference PCR targeting the *Plasmodium* 18S rRNA genes was used to confirm the *Plasmodium* species using EDTA-whole blood clinical samples, consisting of an initial *Plasmodium* genus (hereafter abbreviated to *P*. genus) nest 1, followed by species-specific nest 2 for *P. falciparum*, *P. vivax*, *P. malariae*, and *P. ovale* spp. (23). The *P. knowlesi*- (24) and *P. cynomolgi*-specific (25) reference assays used also target 18S rRNA genes. The *P. knowlesi* reference assay has a previously reported high sensitivity (LOD less than 10 parasite genomes) when validated without reverse transcription (RT) against four *P. knowlesi* strains (Malayan, H, Philippine, and Hackeri); specificity was assessed against the major human *Plasmodium* species in addition to other simian *Plasmodium* species present in Southeast Asia including *P. cynomolgi*, *P. inui*, and *P. simiovale* (24).

Selection of PCR assays for LOD evaluation

A reverse transcriptase real-time hydrolysis probe (RT-qPCR) assay designed to detect the *P. lasmodium* genus was evaluated for its utility in enhancing LOD (**Figure 1A**) (26). Three published *P. knowlesi* species-specific assays, which have not previously had their LODs evaluated using reverse transcription, were compared to the reference assay (**Figure 1B**). Test A is a qPCR assay (27) in current use in the State Public Health Laboratory (Makmal Kesihatan Awam; MKA) Sabah, Malaysia, for routine *P. knowlesi* malaria detection (28). Test B is a hemi-nested PCR targeting the multicopy *SICAvar* genes, previously validated for *P. knowlesi* detection against *P. falciparum*, *P. vivax*, *P. malariae*, and *P. ovale* spp., in addition to clinical *P. knowlesi* isolates from Sarawak, Malaysia (29). Test C is a nested conventional PCR assay targeting 18S rRNA genes specific for *P. knowlesi* that has been robustly validated against *P. vivax* and other zoonotic *Plasmodium* species (25).

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

Limit of detection evaluation for PCR assays with and without RT The initial microscopy-quantified *Plasmodium* species infected samples collected in DNA/RNA ShieldTM were diluted with malaria-negative whole blood (also at the same manufacturer recommended DNA/RNA ShieldTM ratio) to prepare individual parasite count dilutions ranging between 20 to 0.0002 parasites/µL. Total nucleic acids from samples at each serial parasite count dilution were then extracted and duplicate aliquots prepared. Highcapacity cDNA reverse transcription (Applied BiosystemsTM, Thermo Fisher Scientific, MA, USA) was then performed on one aliquot from each pair. PCR was performed on the paired aliquots to detect P. genus by the qPCR assay (26), followed by species-specific assays for: P. knowlesi by the reference hemi-nested assay (24) and test assays A, B, C (25,27,29); P. vivax (23) and P. cynomolgi (25) by reference assays, in addition to the newly designed P. vivax primers. The LOD was expressed as the lowest parasite count per microlitre of whole blood detected by an individual PCR assay in both amplification replicates (Figure 1C). Limit of detection of P. genus qPCR assay for dried blood spots (DBS) with and without **RT** The LOD for the P. genus qPCR assay was also evaluated using archived DBS from P. knowlesi clinical infections with and without RT (Figure 1C). DBS were stored individually after collection with dessicant at room temperature unexposed to light before processing. Nucleic acids were extracted from the DBS samples, with 10µl immediately reverse transcribed into cDNA. P. genus qPCR was conducted on serial 1:10 DNA and cDNA dilutions with the LOD calculated using the initial enumerated parasitemia divided by the corresponding dilution level. Evaluation of PCR assay specificity on clinical malaria samples For the analysis of *P. knowlesi*, *P. falciparum*, and *P. vivax* clinical isolates, in addition to a *P.* cynomolgi macaque-derived isolate, all samples were individually tested using the P. genus qPCR assay and the three *P. knowlesi*-specific PCR assays. Results were compared against the reference PCR. Specificity for the *P.* genus assay was evaluated for malaria detection (any *Plasmodium* species) versus malaria-negative controls, and for species-specific assays using the corresponding *Plasmodium* species infection versus other *Plasmodium* species and malaria-negative controls combined. Clinical blood samples collected in EDTA likely had RNA degradation upon thawing; therefore, reverse transcription was not performed for this part of the analysis.

Statistical analyses

Parasite counts for each clinical *Plasmodium* species infection were summarised using median and interquartile range (IQR). The median whole blood LOD was calculated with and without reverse transcription for the *P. knowlesi* and *P. vivax* isolates. To calculate the LOD fold-change, the LOD without RT was divided by the LOD with RT. One-way ANOVA was used to test for differences in parasite count distribution across *Plasmodium* species, followed by Student's t-test for pairwise comparisons of log-transformed data. Results of PCR assays evaluated against reference PCR were defined as true positive (TP), false negative (FN), true negative (TN), and false positive (FP), enabling calculation of diagnostic sensitivity (TP/TP+FN) and specificity (TN/TN+FP) with exact binomial 95% confidence intervals. All statistical analyses were performed using Stata version 17.0 (StataCorp, Texas, USA).

RESULTS

Limit of detection of P. genus PCR assays

The LOD was performed on *P. knowlesi* (n=4), *P. vivax* (n=4) and *P. cynomolgi* (n=1) whole blood isolates. For the *P.* genus Kamau et al. qPCR assay, without reverse transcription, the median LOD to detect each individual *Plasmodium* species was 2 parasites/µL (**Table 2** and

Figure 2A). With reverse transcription, the assay sensitivity for *P. knowlesi* improved with a LOD of ≤0.0002 parasites/μL for all four isolates (10,000-fold change). The LOD for both *P. vivax* and *P. cynomolgi* improved to 0.002 parasites/μL with RT (1,000-fold change); Figure 2B. In comparison, the reference Snounu *P.* genus assay had a slightly higher LOD for *P. vivax* and *P. cynomolgi* without RT (0.2 parasites/μL for both); however, with RT a less pronounced improvement in LOD was demonstrated at 0.02 and 0.01 parasites/μL, respectively.

Table 2. Limit of detection (LOD) of *Plasmodium* genus and species-specific PCR assays

PCR assay	Target	Tested	LOD	LOD	Fold change
	Р.	species	without RT	with RT	post RT (x)
	genus/species				
Kamau et al. (26)	P. genus	Pk	2	≤0.0002	10000
Kamau et al. (26)	P. genus	Pv	2	0.002	1000
Kamau et al. (26)	P. genus	Pc	2	0.002	1000
Snounou et al. (23)	P. genus	Pk	2	0.0011	1818
Snounou et al. (23)	P. genus	Pv	0.2	0.02	10
Snounou et al. (23)	P. genus	Pc	0.2	0.01	20
Imwong et al. (24)	Pk	Pk	2	0.0007	2759
Divis et al. (27)	Pk	Pk	0.2	≤0.0002	1000
Lee et al. (25)	Pk	Pk	11	11	No change
Lubis et al. (29)	Pk	Pk	0.11	1.1	0.1*
Snounou et al. (23)	Pv	Pv	20	0.02	1000
Snounou et al. (23)	Pv	#Pc	0.2	0.02	10
Lee et al. (25)	Pc	Pc	2	0.2	10

Abbreviations: P. genus = Plasmodium genus; Pk = P. knowlesi; Pv = P. vivax; Pc = P. cynomolgi; RT = reverse transcription

LOD is the lowest parasitemia (parasites/µL) detected by all three replicates for each PCR assay

LOD and fold-change post RT are reported as median for *P. knowlesi* (n=4)

^{*}There was no improvement in LOD by Lubis PCR assay (Test B) after RT

^{*}P. vivax assay cross-reacts with P. cynomolgi

264

265

266

267

268

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

Limit of detection of *Plasmodium* species-specific PCR assays For the *P. knowlesi*-specific assays, the median LOD without and with reverse transcription was 2 and 0.0007 parasites/μL, respectively, for the Imwong et al. reference assay (2759-fold change); 0.2 and 0.0002 parasites/µL, respectively, for Test A (1000-fold); 0.11 and 1.1 parasites/µL, respectively, for Test B (no improvement); and 11 parasites/µL for both (no change) for Test C (Table 2 and Figure 2A). Without reverse transcription, the LODs using species-specific reference assays were 2 parasites/µL for P. cynomolgi and 20 parasites/µL for P. vivax. With reverse transcription, the LODs were 0.2 (10-fold change) and 0.02 (1000-fold change) for P. cynomolgi and P. vivax respectively. However, additional testing of the P. cynomolgi isolate using the reference P. vivax-targeted rVIV1/rVIV2 primers (23) amplified this target from the macaque-origin P. cynomolgi infection both without (0.2 parasites/µL) and with reverse transcription (0.02 parasites/µL), producing a false-positive P. vivax result (**Table 2 and Figure 2B**). The LOD with reverse transcription of the P. genus assay was comparable to the LOD of the best performing species-specific assay for P. knowlesi detection (<0.0002 parasites/µL for both). In contrast, the P. genus assay had a superior LOD compared to the reference speciesspecific assays for P. vivax (0.002 vs 0.02 parasites/µL respectively) and P. cynomolgi (0.002 vs 0.2 parasites/µL respectively). Limit of detection of *P*. genus qPCR for dried blood spots (DBS) The median LOD between DNA and cDNA generated from dried blood spots (DBS) for 4 P. knowlesi extracted samples collected 8 months prior to evaluation of the P. genus Kamau 2011 assay without and with RT was 19.86 and 0.08 parasites/uL, respectively (249-fold change); **Table 3.** Archived DBS samples (n=12) collected more than 6 years (up to 11 years) prior to extraction demonstrated a similar LOD with and without RT (median 20 parasites/µL).

Table 3. Limit of detection of the 18S rRNA P. genus qPCR assay for P. knowlesi dried blood spot samples

Species evaluated	Initial parasitemia (/µL)	Time from DBS collection	LOD without RT (DNA)	LOD with RT (cDNA)	Fold change post RT (x)		
Recent sam	ıples						
Pk	2663	8 months	26.6	0.027	1000		
Pk	1377	8 months	13.8	0.138	100		
Pk	198	8 months	2.0	0.020	100		
Pk	26	8 months	26.0	2.600	10		
Median	788	8 months	19.9	0.08	100		
(IQR)	(198-1377)		(13.8-26.0)	(0.03-0.14)	(100-100)		
Archived samples [†]							
Pk	372	11 years	20	20	1		
(N=12)	(177-2604)	(8-11)*	(2.5-20)	(2-20)	(1-1.25)		

Limit of detection (parasites/µL) with and without RT of each *P. knowlesi* isolate was conducted in duplicate for each target species at each dilution level.

Specificity of P. genus and individual Plasmodium species PCR assays

A total of 239 samples were included in the clinical evaluation of test specificity without RT, consisting of 96 *P. knowlesi*, 50 *P. vivax*, 44 *P. falciparum*, and 1 *P. cynomolgi* infected samples, and 48 malaria-negative controls. The median parasitemia was 1,957/μL (IQR 261-5,762; range 27-210,100 parasites/μL) for *P. knowlesi*, 3,246/μL (IQR 1,588-7,306; range 77-20,064 parasites/μL) for *P. vivax*, and 14,015/μL (IQR 2,193-33,413; range 34-297,000 parasites/μL) for *P. falciparum*.

The *P.* genus qPCR screening assay was both 100% specific and sensitive for the detection of *Plasmodium* species overall compared to the reference PCR, with all 48 samples from uninfected controls confirmed as malaria-negative.

[†] Results are median (IQR)

^{*}Range from 6 to 11 years

Pk = P. knowlesi

P. knowlesi- assays for Tests A (27) and B (29) correctly identified all 96 *P. knowlesi* and 95 non-*P. knowlesi* samples, resulting in 100% specificity and sensitivity. Test C (25) was negative for a single *P. knowlesi* isolate with a parasite count of 1,535 parasites/μL, resulting in 99% (95% CI 94.3-100.0) sensitivity and 100% specificity. The reference assays for *P. falciparum* and *P. vivax* (23), and for *P. cynomolgi* (25) were negative for all *P. knowlesi* clinical isolates tested (**Table 2**).

DISCUSSION

Malaria-susceptible countries in most of Southeast Asia, including those approaching or achieving WHO elimination of major human-only *Plasmodium* species, remain at-risk for zoonotic malaria transmission (30,31). Understanding regional heterogeneity in *P. knowlesi* transmission intensity and disease morbidity will require the selective deployment of highly sensitive and specific molecular detection tools for both diagnostic and surveillance purposes (19). Our major finding demonstrated that the use of a reverse-transcription step after extraction of preserved total nucleic acids in clinical samples considerably improves the limit of detection of both the selected *P.* genus RT-qPCR screening assay, and *P. knowlesi*-specific assays (reference and Test A; both >1000-fold) by additionally amplifying ribosomal RNA sequences. The enhanced limit of detection was consistent across both field-stable DNA/RNA ShieldTM samples and to a lesser degree in recent (although not older) dried blood spots. The second key finding of this study was the excellent performance of the *P.* genus screening assay, originally developed and validated for use in an African context for *P. falciparum* (26), to detect previously unvalidated species including *P. knowlesi*, *P. cynomolgi* and *P. vivax*. The specificity of each of the *P. knowlesi*-targeted assays to exclude *P. cynomolgi* and non-zoonotic

336

337

338

339

340

341

342

343

344

345

346

347

348

349

350

351

352

353

354

355

356

357

358

359

Plasmodium species was confirmed to be excellent. Together these findings highlight the potential utility of incorporating these assays in a molecular surveillance approach to detect both human and zoonotic *Plasmodium* species that are well below the reported parasite count detection limits for current conventional PCR, loop-mediated isothermal amplification, microscopy or parasite lactate-dehydrogenase-based rapid diagnostic tests (19). The community-based detection of submicroscopic P. knowlesi and P. cynomolgi infections, both symptomatic or asymptomatic, requires ultrasensitive molecular tools to understand the true extent of population-level transmission (19). Recent studies in areas of both Peninsular Malaysia and the East Malaysian state of Sarawak have reported human infections in local communities living in or near forested areas with other macaque malaria species, including P. inui, P. coatneyi, P. fieldi and possibly P. simiovale, in addition to P. knowlesi and P. cynomolgi (32). It is unclear whether or to what extent these low-level zoonotic infections may facilitate onward transmission to humans (33,34), as occurs with low parasitemia P. falciparum and P. vivax infections (35,36), although sustained human-to-human transmission of P. knowlesi has not been evident to date(25,37). The selection of the major RT-qPCR P. genus screening assay aimed to maximise the detection limits for low-level zoonotic *Plasmodium* species infections due to the known high multicopy number (5 to 10 copies per genome depending on the *Plasmodium* species) of the 18S rRNA target (38), in addition to amplification of both the A- and S- type genes and their RNA transcripts (26). The excellent LOD demonstrated with the P. genus RT-qPCR assay in the current study of <0.0002 parasites/µL for P. knowlesi detection is consistent with a previously reported extremely low LOD of ~0.0004 parasites/μL for clinical *P. falciparum* samples (26). DNA-concentrated packed red blood cell samples have been demonstrated to further improve

361

362

363

364

365

366

367

368

369

370

371

372

373

374

375

376

377

378

379

380

381

382

383

384

sensitivity for P. falciparum detection in population-based malaria prevalence surveys in elimination areas of Thailand (39). Comparable performance to this P. genus RT-qPCR assay was reported with a separately established ultrasensitive quantitative PCR method (uPCR) with a limit of detection of 0.022 parasites/µL (39), however, a major advantage of the reverse transcriptase qPCR assay is the requirement for comparatively lower blood volumes (18). Interestingly, in the current study the conventional PCR P. genus reference assay also demonstrated a large increase in analytical sensitivity after reverse transcription (~1800-fold) and may provide a more cost-effective option compared to qPCR for surveillance purposes. DNA/RNA ShieldTM was selected as the preferred blood collection preservation method over other media due to its reported ability to stabilise DNA/RNA at ambient temperatures in field settings and compatibility with most DNA and RNA purification kits for subsequent highthroughput workflows including reverse transcription (40). To date, only a few studies have incorporated reverse transcription in the molecular detection of *Plasmodium* species (41,42). The reverse transcription step in the present study improved the analytical sensitivity of our selected assays to detect zoonotic P. knowlesi, P. cynomolgi and other human malaria infections by up to 10,000-fold (*Plasmodium* genus), 2759-fold (*P.* knowlesi), 1000-fold (P. vivax) and 10-fold (P. cynomolgi), respectively. The P. knowlesispecific hemi-nested reference assay with reverse transcription demonstrated a comparable limit of detection to the qPCR Test A (which requires an expensive real-time hydrolysis probe), and was superior to both Test B targeting SICavar and Test C targeting the 18S rRNA gene. Without reverse transcription, the lowest limit of detection for *P. knowlesi* was seen with Test B, suggesting that the multiple chromosomal copies of the variant antigen SICAvar provide equivalent or better signal amplification than the detection of transcripts from whichever of these gene copies is activated in any particular parasite cell in the peripheral blood. Constraints

386

387

388

389

390

391

392

393

394

395

396

397

398

399

400

401

402

403

404

405

406

407

408

409

on the widespread use of reverse transcription include the additional cost, laboratory time, and the usual rapid degradation of RNA molecules in field or laboratory settings. However, the degree of RNA amplification with reverse transcription was aided in our study by collecting blood samples in room-temperature stable RNA preservation media suitable for field-based surveillance, which also allows other potential downstream pathophysiological or transcriptomic analyses dependent on pathogen or host RNA transcripts. The low reported limit of detection for the RT-qPCR P. genus assay conducted on DBS in this study (~0.08 parasites/µL with reverse transcription) suggests this type of sample collection would also enable the identification of a large proportion of submicroscopic and/or asymptomatic infections. DBS collection is logistically a more feasible, inexpensive and acceptable option particularly for asymptomatic or younger participants (given the need for fingerprick blood collection rather than venepuncture) for large-scale malaria surveillance surveys. However, the reverse transcription step only improved the LOD in DBS samples that were collected within 8 months; older DBS stored in recommended conditions for more than 6 years did not provide any improvement in the LOD with and without RT due to likely degradation of RNA. Regardless, the P. genus LOD of around 2 to 20 parasites/µL without RT for DBS samples remains encouraging as a first-line option for surveillance screening purposes, although the use of DBS would require further evaluation with *Plasmodium* species-specific PCR assay differentiation. The current study confirmed previous findings detailing cross-reactivity between the nested PCR primers for P. vivax (rVIV1/rVIV2) with P. cynomolgi (13). A single mismatch in the 30 nucleotides of the rVIV2 primer sequences was reported to cross-amplify P. cynomolgi isolates (13). The nested P. vivax-specific assay using the same primers rVIV1/rVIV2 designed to

411

412

413

414

415

416

417

418

419

420

421

422

423

424

425

426

427

428

429

430

431

432

433

target the 18S rRNA gene also amplified P. cynomolgi in our LOD analysis (23). The separate P. cynomolgi primers remained highly specific and did not erroneously amplify P. vivax or other closely related *Plasmodium* species DNA. In practice, the concurrent use of both assays would enable accurate identification of a P. vivax mono-infection, however, this approach would not be able to differentiate a P. vivax/P. cynomolgi co-infection from a P. cynomolgi mono-infection. Mis-identification of symptomatic P. cynomolgi infections as P. vivax would not result in inappropriate treatment, given both have a latent hypnozoite liver life-stage requiring additional radical cure with primaquine. Most other commonly used single-round multiplex (43) and qPCR assays (44) containing P. vivax-specific targets have also not been validated against isolates of P. cynomolgi or other closely related macaque Plasmodium species. However, a variety of sequencing approaches of targeted gene amplicons including mitochondrial COX1 and cytochrome b, SICAvar and SSU 18S rRNA followed by sequencing and reference alignment have been used to confirm unknown or mixed zoonotic Plasmodium species infections following initial ambiguous PCR results (45,46). A limitation of this study was the inability to validate submicroscopic clinical P. knowlesi infections and other zoonotic species such as P. fieldi, P. inui and P. coatneyi for which samples were not available. Due to the increasing number of published *P. knowlesi* assays, we were not able to evaluate other P. knowlesi assays of possibly comparable performance within our selected workflow. We were also unable to evaluate mixed infections of P. knowlesi, P. vivax and P. falciparum despite these cases being reported in certain areas such as Indonesia (29) and Vietnam (47). Due to sample availability, we were also restricted to only a single P. cynomolgi sample to determine the LOD of the P. cynomolgi-specific assay (25). The discrepancy between the LOD for the P. genus qPCR screening assay and the species-specific assay for *P. cynomolgi* detection may mean a proportion of very low-level *P. cynomolgi* infections are unable to be identified beyond a *P.* genus threshold using the current protocol.

CONCLUSIONS

The *Plasmodium* genus reverse transcriptase qPCR assay can provide highly sensitive screening for zoonotic and human malaria, including for submicroscopic infections in at-risk populations in endemic areas. The use of this molecular surveillance protocol for either whole blood or DBS collected samples in understudied areas of Southeast Asia would enable improved understanding of the regional disease burden and transmission dynamics of zoonotic malaria. Enhanced molecular tools and future iterative improvements to conventional surveillance protocols are especially critical as Southeast Asia continues to exert considerable public health efforts towards human malaria elimination despite the challenge of additional zoonotic *Plasmodium* species infections at an expanding human-animal-interface.

DECLARATIONS

Ethics approval and consent to participate

Sample collection and diagnostic evaluation were approved as part of prospective malaria studies by the Medical Research and Ethics Committee (MREC), Ministry of Health Malaysia (NMRR-10-754-6684, NMRR-19-4109-52172 and NMRR-19-3229-49967), Universitas Sumatera Utara, Indonesia (#723/KEP/USU/2021) and by the Menzies School of Health Research, Australia (HREC-2010-1431 and HREC-2022-4417) in accordance with all applicable Federal and other regulations governing the protection of human subject research.

457

458

459

460

461

462

463

464

465

466

467

468

469

470

471

472

473

474

475

476

477

Authors' contributions

Competing interests The authors declare that they have no competing interests. **Funding** This work was supported by the ZOOMAL project, funded through the Australian Centre for International Agricultural Research and Indo-Pacific Centre for Health Security, DFAT, Australian Government (#LS-2019-116), the National Institutes of Health, USA (#R01AI160457-01), and DOD-DHA-Global Emerging Infections Surveillance program project P0097 22 N2.). Funding support was also through the National Health and Medical Research Council, Australia (Grant Numbers #1037304 and #1045156, fellowship to NMA [#1042072], Emerging Leadership 2 Investigator Grants to MJG [#2017436] and BEB [#2016792]), and the Ministry of Health, Malaysia (#BP00500/117/1002) awarded to GSR. **Disclaimers** The views expressed are those of the author(s) and do not necessarily reflect the official policy or position of the Department of the Navy, Department of Defense, nor the U.S. Government. Copyright Statement: NC (LCDR, MSC, USN) & AL (CAPT, MC, USN) are military service members and employees of the U.S. Government. This work was prepared as part of their official duties at U.S. Naval Medical Research Unit INDO PACIFIC. Title 17 U.S.C. §105 provides that 'Copyright protection under this title is not available for any work of the United States Government.' Title 17 U.S.C. §101 defines a U.S. Government work as a work prepared by a military service member or employee of the U.S. Government as part of that person's official duties.

21

478 Conceptualization, funding acquisition, methodology and resources: MG, NA, KB, KP, INL, 479 RN, CP, NC, AL. Sample processing and conduct of assays: KP and PK. Data analyses: KB, MG, KP. Initial manuscript preparation and writing: KB, MG. All authors read and approved 480 481 the final manuscript. 482 Acknowledgements 483 We thank the study participants, the IDSKKS malaria research team (Mohd Rizan Osman, 484 Danshy Alaza, Azielia Elastiqah, Sitti Saimah binti Sakam), and Bruce Russell of the 485 Department of Microbiology & Immunology, University of Otago, Dunedin, New Zealand, for 486 providing the *P. cynomolgi* isolate. We thank the Director General of Health Malaysia for the 487 permission to publish this article. 488 489 490 491 **REFERENCES** 492 493 1. Moyes CL, Henry AJ, Golding N, Huang Z, Singh B, Baird JK, et al. Defining the 494 Geographical Range of the *Plasmodium knowlesi* Reservoir. PLoS Neglected Trop Dis. 495 2014;8(3):e2780. 496 2. Cuenca PR, Key S, Jumail A, Surendra H, Ferguson HM, Drakeley C, et al. Epidemiology 497 of the zoonotic malaria Plasmodium knowlesi in changing landscapes. Adv Parasit. 498 2021;113:225–86. 499 3. Barber BE, William T, Grigg MJ, Menon J, Auburn S, Marfurt J, et al. A Prospective 500 Comparative Study of Knowlesi, Falciparum, and Vivax Malaria in Sabah, Malaysia: High

502

503

504

505

507

508

509

510

511

512

513

514

515

516

517

518

519

520

521

Proportion With Severe Disease From Plasmodium knowlesi and Plasmodium vivax But No Mortality With Early Referral and Artesunate Therapy. Clin Infect Dis. 2013 Feb;56(3):383– 97. 4. Daneshvar C, Davis TME, Cox-Singh J, Rafa'ee MZ, Zakaria SK, Divis PCS, et al. Clinical and laboratory features of human *Plasmodium knowlesi* infection. Clinical Infectious 506 Diseases [Internet]. 2009 Sep 15;49(6):852–60. Available from: http://cid.oxfordjournals.org/lookup/doi/10.1086/605439 5. Grigg MJ, William T, Barber BE, Rajahram GS, Menon J, Schimann E, et al. Age-Related Clinical Spectrum of *Plasmodium knowlesi* Malaria and Predictors of Severity. Clin Infect Dis. 2018 Aug 1;67(3):350-9. 6. Kotepui M, Masangkay FR, Kotepui KU, Milanez GDJ. Preliminary review on the prevalence, proportion, geographical distribution, and characteristics of naturally acquired Plasmodium cynomolgi infection in mosquitoes, macaques, and humans: a systematic review and meta-analysis. BMC Infect Dis. 2021;21(1):259. 7. Grigg MJ, Lubis IN, Tetteh KKA, Barber BE, William T, Rajahram GS, et al. *Plasmodium* knowlesi detection methods for human infections—Diagnosis and surveillance. In: Advances in Parasitology [Internet]. Academic Press; 2021. p. 77–130. (Drakeley C, editor. Advances in Parasitology; vol. 113). Available from: https://www.sciencedirect.com/science/article/pii/S0065308X21000270 8. WHO. Malaria Policy Advisory Group (MPAG) meeting (March 2022) [Internet]. 2022 Apr. Available from: https://www.who.int/publications/i/item/9789240048430

523

524

525

526

527

528

529

530

531

532

533

534

535

536

537

538

539

540

541

542

543

9. Barber BE, William T, Grigg MJ, Yeo TW, Anstey NM. Limitations of microscopy to differentiate *Plasmodium* species in a region co-endemic for *Plasmodium falciparum*, Plasmodium vivax and Plasmodium knowlesi. Malaria J. 2013 Jan 8;12(1):8. 10. Lee KS, Cox-Singh J, Singh B. Morphological features and differential counts of Plasmodium knowlesi parasites in naturally acquired human infections. Malaria J. 2009 Apr 23;8(1):73–73. 11. Coutrier FN, Tirta YK, Cotter C, Zarlinda I, González IJ, Schwartz A, et al. Laboratory challenges of *Plasmodium* species identification in Aceh Province, Indonesia, a malaria elimination setting with newly discovered *P. knowlesi*. PLoS Neglected Trop Dis [Internet]. 2018;12(11):e0006924. Available from: https://doi.org/10.1371/journal.pntd.0006924 12. Hartmeyer GN, Stensvold CR, Fabricius T, Marmolin ES, Hoegh SV, Nielsen HV, et al. Plasmodium cynomolgi as Cause of Malaria in Tourist to Southeast Asia, 2018. Emerging infectious diseases. 2019 Oct;25(10):1936-9. 13. Ta TH, Hisam S, Lanza M, Jiram AI, Ismail N, Rubio JM. First case of a naturally acquired human infection with *Plasmodium cynomolgi*. Malaria J. 2014;13(1):68. 14. Barber BE, William T, Grigg MJ, Piera K, Yeo TW, Anstey NM. Evaluation of the Sensitivity of a pLDH-Based and an Aldolase-Based Rapid Diagnostic Test for Diagnosis of Uncomplicated and Severe Malaria Caused by PCR-Confirmed Plasmodium knowlesi, Plasmodium falciparum, and Plasmodium vivax. J Clin Microbiol. 2013 Apr 1;51(4):1118– 23. 15. Grigg MJ, William T, Barber BE, Parameswaran U, Bird E, Piera K, et al. Combining Parasite Lactate Dehydrogenase-Based and Histidine-Rich Protein 2-Based Rapid Tests To

545

546

547

548

549

550

551

552

553

554

555

556

557

558

559

560

561

562

563

564

565

Improve Specificity for Diagnosis of Malaria Due to Plasmodium knowlesi and Other Plasmodium Species in Sabah, Malaysia. J Clin Microbiol. 2014 Apr;52(6):2053-60. 16. Tan AF, Sakam SS binti, Rajahram GS, William T, Isnadi MFAR, Daim S, et al. Diagnostic accuracy and limit of detection of ten malaria parasite lactate dehydrogenasebased rapid tests for *Plasmodium knowlesi* and *P. falciparum*. Front Cell Infect Microbiol [Internet]. 2022;12:1023219. Available from: https://www.frontiersin.org/articles/10.3389/fcimb.2022.1023219 17. Lee PC, Chong ETJ, Anderios F, Lim YA, Chew CH, Chua KH. Molecular detection of human *Plasmodium* species in Sabah using PlasmoNexTM multiplex PCR and hydrolysis probes real-time PCR. Malaria Journal. 2015 Jan 28;14(1):28. 18. Christensen P, Bozdech Z, Watthanaworawit W, Renia L, Malleret B, Ling C, et al. Reverse transcription PCR to detect low density malaria infections. Wellcome Open Res. 2021;6:39. 19. Anstey NM, Grigg MJ. Zoonotic Malaria: The Better You Look, the More You Find. J Infect Dis [Internet]. 2019;219(5):679–81. Available from: https://www.ncbi.nlm.nih.gov/pubmed/30295775 20. Christensen P, Racklyeft A, Ward KE, Matheson J, Suwanarusk R, Chua ACY, et al. Improving in vitro continuous cultivation of *Plasmodium cynomolgi*, a model for *P. vivax*. Parasitol Int. 2022;89:102589. 21. WHO. Microscopy for the detection, identification and quantification of malaria parasites on stained thick and thin blood films in research settings. World Health Organisation [Internet]. 2015; Available from: https://apps.who.int/iris/handle/10665/163782

567

568

569

570

571

572

573

574

575

576

577

578

579

580

581

582

583

584

585

586

587

588

22. Zainabadi K, Adams M, Han ZY, Lwin HW, Han KT, Ouattara A, et al. A novel method for extracting nucleic acids from dried blood spots for ultrasensitive detection of low-density Plasmodium falciparum and Plasmodium vivax infections. Malar J [Internet]. 2017;16(1):377. Available from: https://doi.org/10.1186/s12936-017-2025-3 23. Snounou G, Viriyakosol S, Jarra W, Thaithong S, Brown KN. Identification of the four human malaria parasite species in field samples by the polymerase chain reaction and detection of a high prevalence of mixed infections. Molecular and biochemical parasitology. 1993 Apr;58(2):283–92. 24. Imwong M, Tanomsing N, Pukrittayakamee S, Day NPJ, White NJ, Snounou G. Spurious Amplification of a *Plasmodium vivax* Small-Subunit RNA Gene by Use of Primers Currently Used To Detect P. knowlesi. J Clin Microbiol [Internet]. 2009;47(12):4173–5. Available from: https://www.ncbi.nlm.nih.gov/pubmed/19812279 25. Lee KS, Divis PCS, Zakaria SK, Matusop A, Julin RA, Conway DJ, et al. *Plasmodium* knowlesi: Reservoir Hosts and Tracking the Emergence in Humans and Macaques. Kazura JW, editor. PLoS Pathog. 2011;7(4):e1002015. 26. Kamau E, Tolbert LS, Kortepeter L, Pratt M, Nyakoe N, Muringo L, et al. Development of a Highly Sensitive Genus-Specific Quantitative Reverse Transcriptase Real-Time PCR Assay for Detection and Quantitation of *Plasmodium* by Amplifying RNA and DNA of the 18S rRNA Genes. J Clin Microbiol [Internet]. 2011;49(8):2946–53. Available from: https://www.ncbi.nlm.nih.gov/pubmed/21653767 27. Divis PC, Shokoples SE, Singh B, Yanow SK. A TaqMan real-time PCR assay for the detection and quantitation of *Plasmodium knowlesi*. Malar J [Internet]. 2010;9(1):344. Available from: https://www.ncbi.nlm.nih.gov/pubmed/21114872

- 589 28. Nuin NA, Tan AF, Lew YL, Piera KA, William T, Rajahram GS, et al. Comparative evaluation of two commercial real-time PCR kits (QuantiFastTM and abTESTM) for the 590 591 detection of *Plasmodium knowlesi* and other *Plasmodium* species in Sabah, Malaysia. 592 Malaria J. 2020 Aug;19(1):306. 593 29. Lubis IND, Wijaya H, Lubis M, Lubis CP, Divis PCS, Beshir KB, et al. Contribution of 594 Plasmodium knowlesi to Multispecies Human Malaria Infections in North Sumatera, 595 Indonesia. J Infect Dis [Internet]. 2017;215(7):1148–55. Available from: 596 https://www.ncbi.nlm.nih.gov/pubmed/28201638 597 30. Shearer FM, Huang Z, Weiss DJ, Wiebe A, Gibson HS, Battle KE, et al. Estimating 598 Geographical Variation in the Risk of Zoonotic *Plasmodium knowlesi* Infection in Countries 599 Eliminating Malaria. Churcher TS, editor. PLoS Neglected Trop Dis [Internet]. 600 2016;10(8):e0004915. Available from: https://doi.org/10.1371/journal.pntd.0004915 601 31. Tobin RJ, Harrison LE, Tully MK, Lubis IND, Noviyanti R, Anstey NM, et al. Updating 602 estimates of *Plasmodium knowlesi* malaria risk in response to changing land use patterns 603 across Southeast Asia. PLOS Neglected Trop Dis. 2024;18(1):e0011570. 604 32. Yap NJ, Hossain H, Nada-Raja T, Ngui R, Muslim A, Hoh BP, et al. Natural Human 605 Infections with *Plasmodium cynomolgi*, *P. inui*, and 4 other Simian Malaria Parasites, 606 Malaysia - Volume 27, Number 8—August 2021 - Emerging Infectious Diseases journal -607 CDC. Emerg Infect Dis [Internet]. 2021;27(8):2187–91. Available from: 608 https://www.ncbi.nlm.nih.gov/pubmed/34287122
- 33. Fornace KM, Nuin NA, Betson M, Grigg MJ, William T, Anstey NM, et al.
- 610 Asymptomatic and Submicroscopic Carriage of *Plasmodium knowlesi* Malaria in Household

612

613

614

615

616

617

618

619

620

621

622

623

624

625

626

627

628

629

630

631

and Community Members of Clinical Cases in Sabah, Malaysia. J Infect Dis. 2016 Mar 1;213(5):784-7. 34. Noordin NR, Lee PY, Bukhari FDM, Fong MY, Hamid MHA, Jelip J, et al. Prevalence of Asymptomatic and/or Low-Density Malaria Infection among High-Risk Groups in Peninsular Malaysia. Am J Trop Med Hyg. 2020;103(3):1107–10. 35. Schneider P, Bousema JT, Gouagna LC, Otieno S, Vegte-Bolmer MV de, Omar SA, et al. Submicroscopic *Plasmodium falciparum* gametocyte densities frequently result in mosquito infection. American Journal of Tropical Medicine and Hygiene. 2007;76(3):470-4. 36. Almeida ACG, Kuehn A, Castro AJM, Vitor-Silva S, Figueiredo EFG, Brasil LW, et al. High proportions of asymptomatic and submicroscopic *Plasmodium vivax* infections in a peri-urban area of low transmission in the Brazilian Amazon. Parasites Vectors. 2018;11(1):194. 37. Fornace KM, Topazian HM, Routledge I, Asyraf S, Jelip J, Lindblade KA, et al. No evidence of sustained nonzoonotic Plasmodium knowlesi transmission in Malaysia from modelling malaria case data. Nat Commun. 2023;14(1):2945. 38. Mercereau-Puijalon O, Barale JC, Bischoff E. Three multigene families in *Plasmodium* parasites: facts and questions. Int J Parasitol [Internet]. 2002;32(11):1323-44. Available from: https://www.sciencedirect.com/science/article/pii/S002075190200111X 39. Imwong M, Hanchana S, Malleret B, Renia L, Day NPJ, Dondorp A, et al. Highthroughput ultrasensitive molecular techniques for quantifying low-density malaria parasitemias. Gilligan PH, editor. Journal of clinical microbiology [Internet]. 2014

632 Sep;52(9):3303–9. Available from: 633 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4313154/pdf/zjm3303.pdf 634 40. Eberhardt E, Hendrickx R, Kerkhof MV den, Monnerat S, Alves F, Hendrickx S, et al. 635 Comparative evaluation of nucleic acid stabilizing reagents for RNA- and DNA-based 636 Leishmania detection in blood as proxy for visceral burdens. J Microbiol Methods. 637 2020;173:105935. 638 41. Adams M, Joshi SN, Mbambo G, Mu AZ, Roemmich SM, Shrestha B, et al. An 639 ultrasensitive reverse transcription polymerase chain reaction assay to detect asymptomatic 640 low-density Plasmodium falciparum and Plasmodium vivax infections in small volume blood 641 samples. Malar J. 2015 Dec 23;14(1):520. 642 42. Bousema T, Banman SL, Taylor BJ, Rijpma SR, Morlais I, Yanow SK, et al. A Direct 643 from Blood Reverse Transcriptase Polymerase Chain Reaction Assay for Monitoring 644 Falciparum Malaria Parasite Transmission in Elimination Settings. Am J Trop Med Hyg. 645 2017;97(2):533–43. 646 43. Padley D, Moody AH, Chiodini PL, Saldanha J. Use of a rapid, single-round, multiplex PCR to detect malarial parasites and identify the species present. Ann Trop Med Parasitol 647 648 [Internet]. 2003;97(2):131–7. Available from: https://doi.org/10.1179/000349803125002977 649 44. Rougemont M, Saanen MV, Sahli R, Hinrikson HP, Bille J, Jaton K. Detection of Four 650 Plasmodium Species in Blood from Humans by 18S rRNA Gene Subunit-Based and Species-651 Specific Real-Time PCR Assays. J Clin Microbiol [Internet]. 2004;42(12):5636–43.

Available from: https://journals.asm.org/doi/abs/10.1128/JCM.42.12.5636-5643.2004

652

654

655

656

657

658

659

660

661

662

663

664

665

666

667

668

669

45. Imwong M, Madmanee W, Suwannasin K, Kunasol C, Peto TJ, Tripura R, et al. Asymptomatic Natural Human Infections With the Simian Malaria Parasites *Plasmodium* cynomolgi and Plasmodium knowlesi. J Infect Dis [Internet]. 2019;219(5):695–702. Available from: https://www.ncbi.nlm.nih.gov/pubmed/30295822 46. Putaporntip C, Kuamsab N, Seethamchai S, Pattanawong U, Rojrung R, Yanmanee S, et al. Cryptic Plasmodium inui and Plasmodium fieldi Infections Among Symptomatic Malaria Patients in Thailand. Clin Infect Dis. 2021;75(5):805–12. 47. Marchand RP, Culleton R, Maeno Y, Quang NT, Nakazawa S. Co-infections of Plasmodium knowlesi, P. falciparum, and P. vivax among Humans and Anopheles dirus Mosquitoes, Southern Vietnam - Volume 17, Number 7—July 2011 - Emerging Infectious Diseases journal - CDC. Emerg Infect Dis. 2011;17(7):1232–9.




Figure 1. Limit of detection workflow for (A) P. genus, (B) Plasmodium species-specific, and (C) P. genus dried blood spot PCR assays

Abbreviations: DBS = dried blood spot; LOD = limit of detection; qPCR = real-time quantitative PCR; PR = P. knowlesi; PR =




Figure 2. The median LOD and fold-change with and without reverse transcription for PCR assays to detect *Plasmodium* species.

(A) The median LOD (parasites/μL) for *P.* genus assays using 6 clinical isolates (*P. knowlesi*=4, *P. vivax*=1, *P. cynomolgi*=1) and *P. knowlesi*-specific assays using 4 clinical isolates; (B) The LOD (parasites/μL) for *P. vivax* (n=1) and *P. cynomolgi* (n=1) specific assays. Abbreviations: Pgenus, *Plasmodium* genus; Pk, *P. knowlesi*; Pv, *P. vivax*; Pc, *P. cynomolgi*